NCT02367040 2025-10-14
CHRONOS-3
Bayer
Phase 3 Completed
Clinical Trials
8 trialsNCT02626455 2024-12-11
CHRONOS-4
Bayer
Phase 3 Terminated
NCT01660451 2024-07-17
Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Bayer
Phase 2 Completed
NCT02369016 2023-11-18
CHRONOS-2
Bayer
Phase 3 Completed
NCT02342665 2023-01-20
Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL
Bayer
Phase 1/2 Completed
NCT03498430 2021-05-19
Copanlisib Chinese PK Study
Bayer
Phase 1 Completed
NCT02253420 2020-12-14
COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients
Bayer
Phase 1 Completed
NCT02155582 2017-06-16
Copanlisib Pharmacodynamic Study
Bayer
Phase 1 Completed